Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could an 'Exercise-in-a-Pill' replace workouts for heart failure?

NCT ID NCT05696652

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study from Stanford University is looking at what happens inside the body when people with heart failure exercise. Researchers will measure thousands of proteins in the blood before and after a single workout, and again after a 12-week cardiac rehab program. By comparing these protein changes between those who exercise and those who wait, they hope to find molecules that could one day be turned into medicines that mimic exercise's benefits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
exercise (acute treadmill session and 12-week cardiac rehabilitation)
What this could lead to
If successful, this could identify key proteins that change with exercise, pointing toward new drug targets that mimic exercise benefits for heart failure patients.
What could go wrong
This is an early exploratory study with only 90 participants. It measures protein changes, not clinical outcomes, so it may not lead to any new treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 89 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Male or female, aged 18-89 * Patients must carry a diagnosis of heart failure with ejection fraction \< 40% * Be willing to participate in cardiac rehabilitation, and not already done so in the last year * Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration * Must be able to exercise on a treadmill Exclusion Criteria: * Inability to complete CPET or participate in CR (verbal/chart) * Syncope during CPET within the last 6 mos, sustained VT on CPET, hemodynamically significant arrhythmia during CPET (verbal/chart) * BMI \>= 38 (verbal/chart) * History of a bleeding disorder or clotting abnormality (verbal/chart) * Clinical diagnosis of severe Chronic Obstructive Pulmonary Disease (COPD) (verbal/chart) * History of malignancy not considered in remission (verbal/chart) * Cirrhosis (verbal/chart) * Thyroid disease (verbal/chart) * Thyroid Stimulating Hormone (TSH) value outside of the normal range for the laboratory within the last 1 year * Individuals with hypothyroidism may be referred to their primary care provider (PCP) for evaluation and retested; any medication change must be stable for ≥3 months prior to retesting * Individuals with hyperthyroidism are excluded, including those with normal TSH on pharmacologic treatment * Cancer (verbal/chart) * History of cancer treatment (other than non-melanoma skin cancer) and not "cancer-free" for at least 2 years * Anti-hormonal therapy (e.g., for breast or prostate cancer) within the last 6 months * Chronic active or latent infection (verbal/chart) * Active or latent infections requiring chronic antibiotic or anti-viral treatment * Chronic active infection whether on chronic antimicrobials or not * Human Immunodeficiency Virus * Active hepatitis B or C undergoing antiviral therapy * Individuals successfully treated for hepatitis C and virologically negative for at least 6 months are not excluded * Tobacco (verbal/chart) * Current smokers: any tobacco or e-cigarette/e-nicotine products * Former smokers: Stopped smoking \<6 months at time of screening * Not be pregnant or lactating in the last 12 months, or planning to become pregnant for the next 4 months. Not be post-partum during the last 12 months. (verbal/chart) * Metabolic bone disease (self-report): History of non-traumatic fracture from a standing height or less. Current pharmacologic treatment for low bone mass or osteoporosis, other than calcium, vitamin D, or estrogen. (verbal/chart) * Diabetes (self-report and screening), which includes: i) treatment with any insulin or ii) A1c \>=8.0 (screening). (verbal/chart) * Chronic renal insufficiency (screening): estimated glomerular filtration rate \<30 mL/min/1.73 m2 from serum creatinine (mg/dL) by the Chronic Kidney Disease Epidemiology Collaboration equation. (verbal/chart) * Individuals receiving any active treatment for autoimmune disorders (including monoclonal antibodies) within the last 6 months. (verbal/chart) * Alcohol consumption: i) more than 7 drinks per week for women and more than 14 drinks per week for men; ii) history of binge drinking. (verbal/chart) * Any individual engaging in night shift work in the last 6 months. * Hospitalization for any psychiatric condition within one year (verbal/chart) * Any musculoskeletal or ligamentous injury, amputation or congenital neurological defect that, in the opinion of the team clinician, would negatively impact or mitigate participation in and completion of the protocol. (verbal/chart) * Mental incapacity and/or cognitive impairment on the part of the participant that would inhibit adequate understanding of or cooperation with the study protocol * Other (clinician judgment) * Genetic metabolic disorders that could affect metabolomic results (e.g., phenylketonuria) * Any other cardiovascular, pulmonary, orthopedic, neurologic, psychiatric, metabolic, or other conditions that, in the opinion of the local clinician, would preclude participation and successful completion of the protocol * Any other illnesses that, in the opinion of the local clinician, would negatively impact or mitigate participation in and completion of the protocol * Medication exclusions (chart review) * Androgenic anabolic steroids, antiestrogens, antiandrogens * Growth hormone, insulin like growth factor, growth hormone releasing hormone * Insulin of any type used regularly * Any drugs used specifically to induce muscle growth/hypertrophy or augment exercise induced muscle hypertrophy * Psychiatric * Chronic use of medium- or long-acting sedatives and hypnotics, including all benzodiazepines; short-acting non-benzodiazepine sedative-hypnotics are allowed * Two or more drugs for depression * Mood stabilizers * Antiepileptic drugs * Stimulants, Attention-Deficit/Hyperactivity Disorder (ADHD) drugs * Anti-psychotic drugs * Narcotics and narcotic receptor agonists * Chronic systemic antimicrobials (antibiotic, antiviral, antifungal, antiparasite, etc) for any reason * High-potency topical steroids if ≥10% of surface area using rule of 9s * Continuous/chronic use of antibiotics or other anti-infectives for treatment or prevention * Monoclonal antibodies * Anti-rejection medications/immune suppressants * Any other medications that, in the opinion of local clinicians, would negatively impact or mitigate full participation and completion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Stanford Health Care

    RECRUITING

    Stanford, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.